Современные аспекты тромболитической терапии тромбоэмболии легочных артерий

Концепция тромбоэмболии легочных артерий высокого риска определяет, что верификация окклюзии легочного артериального русла требует проведения таким пациентам срочного восстановления проходимости легочного кровотока. Основным методом лечения тромбоэмболии легочных артерий в настоящее время признана тромболитическая терапия, позволяющая спасти жизнь пациентов, предотвратить развитие хронической постэмболической легочной гипертензии и рецидива тромбоэмболии. В литературном обзоре представлены тромболитические препараты, используемые при лечении тромбоэмболии легочных артерий, описаны показания для проведения тромболитической терапии, сравнительная эффективность и безопасность различных тромболитиков. Описаны основные осложнения тромболитической терапии и затронуты вопросы повышения ее безопасности. Критериями успешности тромболизиса являются ранняя диагностика, точная стратификация риска и адекватное использование реперфузионных средств у больных с тромбоэмболией легочных артерий высокого или промежуточного высокого риска.

1. Бокерия Л.А., Затевахин И.И., Кириенко А.И. и др. Российские клинические рекомендации по диагностике, лечению, профилактике венозных тромбоэмболических осложнений. Флебология. 2015;9(4/2):4–46.

2. Konstantinides S.V., Meyer G., Becattini С. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC), Eur. Heart J. 2020;41(4):543–603. https://DOI.org/10.1093/eurheartj/ehz405

3. Martinez C., Cohen A.T., Bamber L., Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb. Haemost. 2014;112(2):255–263.

4. Wong P., Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism. Phlebology. 2012;27(2–11).

5. Бойцов С.А., Деев А.Д., Шальнова С.А. Смертность и факторы риска неинфекционных заболеваний в России: особенности, динамика, прогноз. Терапевтический архив. 2017;89(1):5–13.

6. Бокарев И.Н. Венозный тромбоэмболизм и тромбоэмболия легочной артерии / И.Н. Бокарев, Л.В. Попова. 2-е изд. Москва: МИА, 2013. 512 с.

7. Jaff M.R., McMurtry M.S., Archer S.L. et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientifi c statement from the American Heart Association. Circulation. 2011;123(16)1788–1830.

8. Alikhan R., Peters F., Wilmott R., Cohen A.T. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J. Clin. Pathol. 2004;57:1254–1257.

9. Turetz M., Sideris A.T., Friedman O.A. et al. Epidemiology, pathophysiology, and natural history of pulmonary embolism. Semin. Intervent. Radiol. 2018;35(2)92–98.

10. Кириенко А.И., Андрияшкин В.В., Леонтьев С.Г. и др. Тромбоэмболия легочной артерии. Кардиология: национальное руководство. Под ред. Е.В. Шляхто. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015;34:712–722.

11. Злочевский П.М. Тромбоэмболия легочной артерии. М.: Медицина, 1978:128.

12. Jaff M.R., McMurtry M.S., Archer S.L. et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–1830.

13. Verstraete M., Miller G.A., Bounameaux H. et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation. 1998;77:353–360.

14. Jaber W.A., Fong P.P., Weisz G. et al. Acute pulmonary embolism: with an emphasis on an interventional approach. J. Am. Coll. Cardiol. 2016;67(8):991–1002.

15. Ватутин Н.Т., Тарадин Г.Г., Канишева И.В. и др. Роль интервенционных методов в лечении острой легочной эмболии. Архивъ внутренней медицины. 2018;5:346–360.

16. Corrigan D., Prucnal C., Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin. Exp. Emerg. Med. 2016;3(3):117–125. DOI: 10.15441/ceem.16.146.

17. Jiménez D., Aujesky D., Moores L. et al. RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch. Intern. Med. 2010;170(15):1383–9. DOI: 10.1001/archinternmed.2010.199

18. De Gregorio M.A., Guirola J.A., Lahuerta C. et al. Interventional radiology treatment for pulmonary embolism. World J. Radiol. 2017;9(7):295–303.

19. Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162)1386–1389.

20. Torbicki A., Perrier A., Konstantinides S. et al. ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology. Eur. Heart. J. 2008;29:2276– 2315.

21. Хубулава Г.Г., Садовой С.В., Гаврилов Е.К. Современные тенденции в хирургическом лечении массивной тромбоэмболии легочной артерии (обзор литературы). Вестник хирургии имени И.И. Грекова. 2019;178(6):66–70. https://DOI.org/10.24884/0042-4625-2019-178-6-66-70

22. Murphy E., Lababidi A., Reddy R. et al. The role of thrombolytic therapy for patients with a submassive pulmonary embolism. Cureus. 2018;10(6):e2814. DOI: 10.7759/cureus.2814

23. Никитина О.В., Михайлов И.П., Кудряшова Н.Е. и др. Тромболитическая и антикоагулянтная терапия при тромбоэмболии легочной артерии: влияние на легочную перфузию (часть 2). Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. 2018;7(2):134–143. DOI: 10.23934/2223-9022-2018-7-2-134-143

24. Browse N.L., James D.C. Streptokinase and pulmonary embolism. Lancet. 1964;2:1039–1043.

25. Konstantinides S., Geibel A., Olschewski M. et al. Association between thrombolytic treatment and the prognosis of hemo dynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96:882–888.

26. Hao Q., Dong B.R., Yue J. et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst. Rev. 2015;9. [Electronic resource] URL: https://www.cochranelibrary.com/cdsr/ DOI: 10.1002/14651858. СD 004437.pub4/full

27. Leopold J.A., Loscalzo J. Pharmacology of thrombolytic agents. Thrombosis and Hemorrhage. J. Loscalzo, A.I. Shafer. 3rd ed. Philadelphia : Lippincott Williams & Wilkins, 2003:949–977.

28. Toquero J., Silva L. Allergic reaction to streptokinase. Revistaespañola de cardiología. 2001;54(10):1225.

29. Trukhanova I.G. Experience of the application of prourokinase recombinant at the pre-hospital stage in patients with acute coronary syndrome. Clinical pharmacology and therapy. 2010;3:60–65. (in Russian)

30. Karaskov A.M., Karpenko A.A., Chernyavsky A.M. et al. Thrombolytic therapy of pulmonary embolism pulmonary artery recombinant activator plas minogen lessonsonazo type Purolaza: medical technology: FS № 2011/104 of 12.05.2011. Novosibirsk, 2010:16. (in Russian)

31. Konstantinides S., Geibel A., Heusel G. et al. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N. Engl. J. Med. 2002;347(15):1143–50.

32. Virk H.U.H., Chatterjee S., Sardar P. et al. Systemic thrombolysis for pulmonary embolism: evidence, patient selection, and protocols for management. Interv. Cardiol. Clin. 2018;7(1):71–80. DOI: 10.1016/j.iccl.2017.08.001.

33. Kucher N., Goldhaber S.Z. Management of massive pulmonary embolism. Circulation. 2005;112:28–32.

34. Konstantinides S., Geibel A., Olschewski M. et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96:882–888.

35. Konstantinides S., Geibel A., Heusel G. et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N. Engl. J. Med. 2002;347(15):1143–1150.

36. Righini M., Roy P.M., Meyer G. et al. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism. J. Thromb. Haemost. 2011;9(10):2115–2117.

37. Wan S., Quinlan D.J., Agnelli G., Eikelboom J.W. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: meta-analysis of the randomized controlledtrials. Circulation. 2004;110(6):744–749.

38. Kasper W., Konstantinides S., Geibel A. et al. Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism; results of a multicenter registry (MAPPET). J. Am. Coll. Cardiol. 1997;30:1165–1171.

39. Tapson V.F. Acute pulmonary embolism. N. Engl. J. Med. 2008; 358(10):1037–1052.

40. Wan S., Quinlan D.J., Agnelli G., Eikelboom J.W. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: meta-analysis of the randomized controlledtrials. Circulation. 2004;110(6):744–749.

41. Becattini C., Agnelli G., Lankeit M. et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur. Respir. J. 2016;48(3):780– 6. DOI: 10.1183/13993003.00024-2016

42. Meyer G., Vicaut E., Danays T. et al. PEITHO Investigators. Fibrino lysis for patients with intermediate-risk pulmonary embolism. N. Engl. J. Med. 2014;370(15):1402–11. DOI: 10.1056/NEJMoa1302097

43. Chatterjee S., Chakraborty A., Weinberg I. et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414–2421. DOI: 10.1001/jama.2014.5990

44. Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017;38(1):56–65. DOI: 10.1055/s-0036-1597560

45. Newman D.H., Greenwalk I., Callaway C.W. Cardiac arrest and the role of thrombolytic agents. Ann. Emerg. Med. 2000;35(5):472–80.

46. Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017;38(1):56–65. DOI: 10.1055/s-0036-1597560

47. Miranda C.H. Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. J. Bras Pneumol. 2019;45(1):e20180297. DOI: 10.1590/1806-3713/e20180297

48. Goldhaber S.Z., Kessler C.M., Heit J. et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2(8606):293–298.

49. Meyer G., Sors H., Charbonnier B. et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J. Am. Coll . Cardiol. 1992;19:239–245.

50. Meneveau N., Schiele F., Vuillemenot A. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur. Heart J. 1997;18:1141–1148.

51. Meneveau N., Schiele F., Metz D. Comparative efficacy of a twohour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J. Am. Coll. Cardiol. 1998;31:1057–1063.

52. Levine M., Hirsh J., Weitz J. et al. A randomised trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98:1473– 1479.

53. Dalen J.E., Alpert J.S., Hirsh J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch. Intern. Med. 1997;157:2550–2256.

54. Goldhaber S.Z., Agnelli G., Levine M.N. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. Chest. 1994;106:718–724.

55. Sors H., Pacouret G., Azarian R. et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest. 1994;106:712–717.

56. Konstantinides S., Geibel A., Heusel G. et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N. Engl. J. Med. 2002;347(15):1143–1150.

57. Smithburger P.L., Campbell S., Kane-Gill S.L. Alteplase treatment of acute pulmonary embolism in the intensive care unit. Crit. Care Nurse. 2013;33(2):17–27.

58. Kline J.A., Hernandez-Nino J., Jones A.E. Tenecteplase to treat pulmonary embolism in the emergency department. J. Thromb. Thrombolysis. 2007;23(2):101–105.

59. Tebbe U., Graf A., Kamke W. et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am. Heart J. 2009;138(1):39–44.

60. Meyer G., Vicaut E., Danays T. et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N. Engl. J. Med. 2014;370(15):1402–1411.

61. Kline J.A., Nordenholz K.E., Courtney D.M. et al. Treatment of sub massive pulmonary embolism with tenecteplase or placebo: car diopulmonary outcomes at 3 months: multicenter doubleblind, placebo-controlled randomized trial. J. Thromb. Haemost. 2014;12(4):459–468.

62. Leontiev S.G., Mironov A.V., Ustinov F.S. Complications of thrombolytic therapy of massive pulmonary embolism. Flebology. 2013;1:55–61. (in Russian)

63. Stein P.D., Matta F., Steinberger D., Keyes D. Intracerebral Hemorrhage with Thrombolytic Therapy for Acute Pulmonary Embolism. Am. J. Med. 2012;125(1):50–56.

64. Agnelli G., Becattini C. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch. Intern. Med. 2002;162:2537–2541.

65. Capstick T., Henry M.T. Efficacy of thrombolytic agents in the treatment of pulmonary embolism. Eur. Respir. J. 2005;26:864–874.

66. Kiser T.H., Burnham E.L., Clark B. et al. Half-dose versus full-dose alteplase for treatment of pulmonary embolism. Crit. Care Med. 2018;46(10):1617–1625. DOI: 10.1097/CCM.0000000000003288

67. Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017;38(1):56–65. DOI: 10.1055/s-0036-1597560

68. Jin Q., Luo Q., Zhao Z. et al. Half-dose versus full-dose alteplase therapy in pulmonary embolism: does half dose really lose? Crit. Care Med. 2018;46(12):e1223–e1224. DOI: 10.1097/CCM.0000000000003384

69. Halaby R., Giri J. Keep it simple? Half-dose systemic thrombolysis or catheter-directed thrombolysis for pulmonary embolism. Vasc. Med. 2019;5:1358863X18824653. DOI: 10.1177/1358863X18824653

70. Овчинников Ю.В., Зеленов М.В. Массивная тромбоэмболия легочной артерии: безопасность тромболитической терапии различными тромболитиками. Военно-медицинский журнал. 2017;3:37–50.